Nanomedicines reveal how PBOV1 promotes hepatocellular carcinoma for effective gene therapy

Yu Guo, Zhiqiang Wu, Shunli Shen, Ruomi Guo, Jing Wang, Weiwei Wang, Kun Zhao, Ming Kuang () and Xintao Shuai ()
Additional contact information
Yu Guo: the First Affiliated Hospital of Sun Yat-Sen University
Zhiqiang Wu: the First Affiliated Hospital of Sun Yat-Sen University
Shunli Shen: the First Affiliated Hospital of Sun Yat-Sen University
Ruomi Guo: the Third Affiliated Hospital of Sun Yat-Sen University
Jing Wang: the First Affiliated Hospital of Sun Yat-Sen University
Weiwei Wang: School of Materials Science and Engineering of Sun Yat-Sen University
Kun Zhao: the First Affiliated Hospital of Sun Yat-Sen University
Ming Kuang: the First Affiliated Hospital of Sun Yat-Sen University
Xintao Shuai: the First Affiliated Hospital of Sun Yat-Sen University

Nature Communications, 2018, vol. 9, issue 1, 1-16

Abstract: Abstract There exists an urgent medical demand at present to develop therapeutic strategies which can improve the treatment outcome of hepatocellular carcinoma (HCC). Here, we explore the biological functions and clinical significance of PBOV1 in HCC in order to push forward the diagnosis and treatment of HCC. Using theranostical nanomedicines, PBOV1 is verified to be a key oncogene which greatly promotes HCC proliferation, epithelial-to-mesenchymal transition, and stemness by activating the Wnt/β-catenin signaling pathway. Therefore, single-chain antibody for epidermal growth factor receptor (scAb-EGFR)-targeted nanomedicine effectively silencing the PBOV1 gene exhibits potent anticancer effects. In vivo HCC-targeting siRNA delivery mediated by the theranostical nanomedicine remarkably inhibits the tumor growth and metastasis. In addition, the superparamagnetic iron oxide nanocrystals (SPION)-encapsulated nanomedicines possess high MRI detection sensitivity, which endows them with the potential for MRI diagnosis of HCC. This study shows that PBOV1 represents a prognostic biomarker and therapeutic target for HCC.

Date: 2018
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-018-05764-7 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-05764-7

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-018-05764-7

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().